

Disclaimer



Cautionary Note Regarding Forward-Looking Information

This presentation contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, plans and objectives. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect," "is expected", "an opportunity exists", "budget", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "does not anticipates", "does not anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "might", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances. This forward-looking information and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Certain assumptions in respect of our ability to execute our growth strategies; our ability to retain key personnel; our ability to maintain and

When relying on forward-looking statements to make decisions, we caution readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved. For further details on the forward-looking information included in this presentation, see "Cautionary Note Regarding Forward-Looking Information" in Andlauer Healthcare Group's Annual Information Form ("AIF) dated March 2, 2023 and the Company's most recent Management Discussion & Analysis ("MD&A"). A number of factors could cause actual results to differ, possibly materially, from the results discussed in the forward-looking statements. Prospective investors should carefully consider the risk factors described in the Company's AIF and most recent MD&A are filed on SEDAR and posted on the Company's website.

Certain statements included in this presentation may be considered a "financial outlook" for purposes of applicable Canadian securities laws, and as such, the financial outlook may not be appropriate for purposes other than this presentation. All forward-looking information in this presentation is made as of the date hereof. Except as expressly required by applicable law, we assume no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements.

Non-IFRS Measures and Industry Metrics

This presentation makes reference to non-IFRS measures, including "EBITDA" and "EBITDA" and "EBITDA" and "EBITDA Margin". These non-IFRS measures do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other companies. They are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Our management will also use non-IFRS measures and in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. Please refer to the Company's most recent MD&A for further discussion of these non-IFRS financial measures and for a reconciliation to comparable IFRS measures, including net income and comprehensive income.

Market and Industry Data

This presentation includes market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information as well as industry data prepared by management on the basis of its knowledge of the healthcare logistics and transportation services industry in which we will operate (including management's estimates and assumptions relating to the industry based on that knowledge).

Management's knowledge of the healthcare logistics and transportation services industry has been developed through its experience and participation in the industry. Management believes that its industry data is accurate and that its estimates and assumptions are reasonable, but there can be no assurance as to the accuracy or completeness of this data. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurances as to the accuracy or completeness of included information. Although management believes it to be reliable, we have not independently verified any of the data from management or third-party sources referred to in this presentation, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Capital Market Profile



IPO: December 2019

TSX: "AND"

SVS market capitalization: \$825 million ⁴

Total market capitalization: \$1.72 billion ⁴

Subordinate Voting Shares ("SVS"): 20,082,328 ¹

Multiple Voting Shares ("MVS"): 21,840,000 12

52-week high / low: \$55.97 / \$40.90 ⁴

IPO issue price: \$15.00 ³

Quarterly dividend: \$0.09 / share (\$0.36 annualized)

Recent share price: \$41.07 4

Dividend yield: ~ 0.8% ⁴

ANALYST COVERAGE















- 1. As at June 30, 2023
- 2. MVS are 100% owned by Andlauer Management Group
- 3. December 11, 2019

- 1. August 4, 2023
- 5. Effective September 2023 (previously \$0.08 per share)

Who we are



Leading and growing supply chain management company with a platform of customized logistics and specialized transportation solutions for the **healthcare** sector in Canada and the U.S.

Four competitive strengths that span our platform and are designed for healthcare customers' needs:

- 1. Temperature management
- 2. Regulatory compliance and quality assurance
- 3. Supply chain visibility
- 4. Security

Platform of companies:









FIVE DEDICATED HEALTHCARE PRODUCT LINES...











...FOCUSED ON A RANGE OF HEALTHCARE END MARKETS



Pharmaceuticals Vaccines **Biologics Blood Products**



Nutraceuticals



Health & Beauty Accessories



Medical

Devices

Consumer



Healthcare

Animal Health











Acquisitions Since IPO



Skelton Canada (Acquired March 2021):

 Validated temperature control, state-of-the-art security systems and real-time monitoring / Leader in 2º C to 8º C and < - 20º C shipments

Skelton USA (Acquired 49% March 2021 / Acquired 100% Nov. 2021):

 Skelton expanded into the U.S. in 2017 due to customer demand and has grown rapidly

Boyle Transportation (Acquired November 2021):

- Based in Massachusetts / operates throughout the 48 contiguous U.S. states and to / from Canada
- Specialized transportation services to life sciences (~ 78% of revenue)
 and government/defense sectors (~ 22% of revenue)

Logistics Support Unit (Acquired March 2022):

 Quebec-based third-party logistics provider offering specialty pharma, warehousing, distribution and order management services throughout Canada







Investment Highlights



- 1 Established Provider of Essential Supply Chain Services to Leading Companies in the Healthcare Industry
 - 2 Coast-to-Coast, Closed-Loop Network in Canada Supported by Specialized Infrastructure
 - Truckload Coverage of the Contiguous 48 U.S. States
 - 4 Technology Supporting a Comprehensive Service Platform
 - **5** Strong Financial Performance
- **6** Experienced Management Team Aligned with Shareholders and Strong Employee Culture

Established Provider of Essential Supply Chain Services





Logistics & Distribution



Packaging Solutions



Ground Transportation



Air Freight Forwarding



Dedicated and Last Mile Delivery

Description	managed transportation, inventory management, secured warehousing, distribution & fulfillment	Co-packing / re-packing, assembly / custom work, design & supply, secondary Rx packaging	Blend of owner-operated and employee drivers, pick-up and delivery, courier, LTL, preferred carrier	Guaranteed contracted space, airport to airport furtherance, dedicated staff	Last mile shipments to pharmacies and veterinarian clinics, pharmacy home-delivery service
Contract	Typically 3 – 5 master service agreements, including quality agreements	Combination of contracts and project-based	Fee for service, often with quality agreements	Fee for service, often with quality agreements	Typically 3 – 5 year contracts
Primary Clients	Pharmaceutical Manufacturers	Pharmaceutical Manufacturers	Third-Party Logistics Providers Wholesalers and Distributors Pharmaceutical Manufacturers	Third-Party Logistics Providers Wholesalers and Distributors Pharmaceutical Manufacturers	Wholesalers Distributors Pharmacies
Geography	Canada-wide	Canada-wide	Canada-wide / U.S.	Canada-wide	Canada-wide (Home delivery in Winnipeg only)
% of Q2 2023 Revenue ¹	23.0%	2.5%	60.5%	4.5%	9.5%
Nevellue			05-		

Brands

























Prior to intersegment revenue eliminations

Partner of Choice for Leading Companies in the Healthcare Industry



LONGSTANDING RELATIONSHIPS WITH MAJOR INDUSTRY PROVIDERS

Strong client retention with an average client relationship across the top 20 clients by revenue of 15+ years

SELECT CLIENT RELATIONSHIPS

Pharmaceutical Manufacturers













Wholesalers and Distributors









Third-Party Logistics Players









Coast-to-Coast, Closed-Loop Network Supported by Specialized Infrastructure





NATIONAL INFRASTRUCTURE



- Nationwide coverage with 31 leased facilities, and six third-party cross-docks
- More than 2.2 million sq. ft. of operating space¹
- GMP-licensed and temperature mapped distribution facilities



TEMPERATURE MANAGEMENT

- Dedicated facilities
- Specialized vehicles
- Customized packaging



QUALITY ASSURANCE

- Highly regulated environment
- Significant GMP and GUI-0069 experience
- Long-standing relationships



SUPPLY CHAIN VISIBILITY

- Proprietary IT systems
- Reporting and regulatory compliance
- Purpose built monitoring system



SECURITY

- Specialized management protocol for high value and controlled products
- Health Canada compliant vaults

1. Square footage excludes cross-docks

Truckload Coverage of the Contiguous 48 U.S. States



Boyle Transportation and Skelton USA have of a combined fleet of 180 trucks and 300 trailers, providing:

- Validated temperature control
- GPS tracking / security monitoring
- Transport of temperature-sensitive pharmaceuticals, biologics and vaccines
- Specialized management protocol for high value and controlled products
- Cross-border service (Canada / U.S.)
- Boyle generates approximately 20-25% of its revenue from U.S. defense sector



Acquisitions of Boyle and Skelton USA forms strategic platform for growth in U.S. market


Technology Supporting a Comprehensive Service Platform



 AHG's proprietary information systems enable end-to-end monitoring, offer complete supply chain visibility and are integrated with those of our clients and end customers

FLEET-INTEGRATED HARDWARE












Strong Financial Performance







EBITDA (\$ millions) / EBITDA Margin (%) 12



- 1. EBITDA is defined as net income (loss) and comprehensive income (loss) for the period before: (i) income tax (recovery) expense; (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization
- 2. Excluding the gain of \$37.9 million on the step acquisition of 51% of Skelton USA Inc. in Q4 2021

Experienced Management Team Aligned with Shareholders



- 200 + combined years working in the logistics, transportation and healthcare industries
- CEO, through AMG, holds ~ 52% interest in AHG, combined with equity ownership by other management team members, ensures strong alignment with shareholders

	Industry Experience	Tenure	Prior Company Experience
Michael Andlauer Chief Executive Officer	37	31	ASSIGNATED LOSS TICK
Peter Bromley CFO and Corporate Secretary	27	4	Even take yas alone.
Stephen Barr President, Transportation	32	13	KPING CALYX Concord
Bob Brogan President, Specialty Solutions	37	21	CP CN
Dean Berg, President, Logistics	28	19	McKesson Logistics Solutions McKesson Logistics Solutions McKesson Logistics Solutions Conditions
Ron Skelton President, Skelton Companies	44	March 2021	Skelton Truck Lines
Andrew Boyle / Marc Boyle Co-Presidents, Boyle Transportation	31/31	November 2021	BOYLE J.P.Morgan McKinsey & Company

Strong Employee Culture



- Strong employee culture has driven AHG forward as an industry leader in high-quality healthcare logistics and transportation services
- Boyle Transportation named the "Best Fleet to Drive For" in the U.S. and Canada (2020 & 2021)
- Skelton Truck Lines selected as a finalist for: Northbridge Insurance Transportation Safety Award (March 2021) and "Best Fleet to Drive For" in the U.S. and Canada (December 2020)













Excellence



Accountability





AHG recognizes its people are its most important asset and promotes personnel from within to retain top talent



Q2 2023 Financial Review




- Year-over-year decline in revenue primarily reflects superior U.S. ground transportation rate premiums, higher revenue related to COVID-19 vaccines and ancillary products, higher fuel surcharges and unusually high air freight forwarding volumes in Q2 2022.
- ~ 0.8% of revenue generated from distribution of COVID vaccines and ancillary products, compared to ~ 2.6% in Q2 2022.

(In 000's, except percentages)	Three months ended June 30, 2023	Three months ended June 30, 2022	Change
Revenue			
Logistics and Distribution	\$ 39,438	\$ 41,845	(5.8)%
Packaging	4,236	6,164	(31.3)%
Healthcare Logistics Segment	43,674	48,009	(9.0)%
Ground Transportation	103,451	106,332	(2.7)%
Air Freight Forwarding	7,678	11,534	(33.4)%
Dedicated and Last Mile Delivery	16,339	17,117	(4.5)%
Less: Intersegment Eliminations	(13,785)	(13,590)	1.4%
Specialized Transportation Segment	113,683	121,393	(6.4)%
Total Revenue	\$ 157,357	\$ 169,402	(7.1)%

Q2 2023 Financial Review





^{1.} EBITDA is defined as net income (loss) and comprehensive income (loss) for the period before: (i) income tax (recovery) expense; (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization

YTD 2023 Financial Review



The year-over-year decline in net income and EBITDA is primarily attributable to reduced contributions from Boyle
Transportation and Skelton USA, lower outbound volume for Accuristix and lower air freight forwarding revenue in
Q2 2023, and the decline in revenue related to COVID-19 vaccines and ancillary products.

(In 000s, except percentages and per share amounts)	Six months ended June 30, 2023	Six months ended June 30, 2022	Variance
Revenue			
Logistics and Distribution	\$ 79,961	\$ 75,090	6.5%
Packaging	9,746	11,922	(18.3)%
Healthcare Logistics Segment	89,707	87,012	3.1%
Ground Transportation	211,711	203,826	3.9%
Air Freight Forwarding	15,220	19,130	(20.4)%
Dedicated and Last Mile Delivery	33,470	32,562	2.8%
Less: Intersegment Eliminations	(27,977)	(24,777)	12.9%
Specialized Transportation Segment	232,424	230,741	0.7%
Total Revenue	322,131	317,753	1.4%
Operating expenses	(275,846)	(263,434)	4.7%
Operating income	46,285	54,319	(14.8)%
Net Income	32,244	37,456	(13.9)%
Foreign currency translation adjustment	(5,239)	3,608	N/A
Total comprehensive income	\$ 27,005	\$ 41,064	(34.2)%
EPS (diluted)	\$ 0.76	\$ 0.88	\$ (0.12)
EBITDA	\$ 80,009	\$ 85,713	(6.7)%
EBITDA Margin	24.8%	27.0%	(220 bps)

Strong Balance Sheet



(in \$000s)	As at June 30, 2023	As at Dec. 31, 2022
Cash and cash equivalents	\$ 84,265	\$ 65,855
Total Assets	709,185	712,460
Debt		
Revolving credit facility		
Term facility	49,691	49,557
Lease liabilities	106,352	113,729
Total Debt	156,043	163,286
Total Liabilities	247,457	271,468
Total Equity	461,728	440,992
Net Debt ¹ / LTM EBITDA ²	0.43x	0.56x

^{1.} Net Debt defined as total debt less cash and cash equivalents

^{2.} LTM EBITDA defined as net income (loss) and comprehensive income (loss) for the trailing 12-month period before: (i) income tax (recovery) expense; (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization



Attractive Industry Fundamentals



- We are well-positioned at the forefront of several accelerating healthcare market trends
- North American outsourced healthcare logistics and transportation market growth outpacing GDP growth

TRENDS DRIVING INDUSTRY GROWTH



Aging Population and Increased Life Expectancy



Increasing Number of Healthcare and Adjacent Products with Unique Logistics Needs





Increasing Industry Regulation



Increasing Demand for Distributed and Ancillary Healthcare Logistics Services

NORTH AMERICAN OUTSOURCED HEALTHCARE LOGISTICS AND TRANSPORTATION MARKET (US\$BN)⁽¹⁾





Organic Growth: Strengthening our Clients' Connection to our Growing Platform



Continued client education and increased regulatory oversight drives increased spending on AHG services


EXPANDING DEDICATED DELIVERY BUSINESS

- Leverage our existing nation-wide network of facilities, dedicated equipment and client relationships
- Expand on regional relationships with existing clients in new geographies and secure new client contracts



ACCURISTIX CAPACITY GROWTH

- AHG has a history of generating growth from new and existing clients
- Adding incremental square footage to serve new clients, while adding excess capacity through capital-efficient leases



DEVELOPING NEW SERVICES

 We are continuously developing new offerings that complement our existing logistics services offering





RA & QA Consulting

Destruction

g Destruction





Clinical Trial Logistics

Medical Devices

Acquisition Growth: Expanding and Strengthening our Platform



Leveraging our core capabilities across a broader array of services to enhance our platform

STRATEGIC APPROACH TO M&A

Increasing scale by completing complementary tuck-in acquisitions



Dedicated & Last Mile Delivery



Ground Transportation



Packaging Solutions



Logistics & Distribution

 Accelerating expansion in growing verticals and gaining expertise in new verticals and geographies



Quality Assurance Consulting



Clinical Trials



Destruction



Geographical Expansion



Primary Packaging



Customs Brokerage



International Freight Forwarding





A Highly Regulated Environment



Regulation and security requirements are increasing in both Canada and abroad

AHG'S KEY COMPANY COMPLIANCE STATUTES, REGULATIONS AND GUIDELINES

- Health Canada's Good Manufacturing Practices Guide for Drug Products (GUI-0001)
- Health Canada's Guidance on Drug Establishment Licenses and Associated Fees (GUI-0002)
- Health Canada's Guidelines for Environmental Control of Drugs During Storage and Transportation (GUI-0069)
- Health Canada's Guidance Document on the Import Requirements for Health Products Under the Food and Drugs Act and its Regulations (GUI-0084)
- Health Canada's Guidelines for Active Pharmaceutical Ingredients (GUI-0104)
- Health Canada's Guidance Documents for Medical Devices
- Health Canada's Guidance Documents for Natural and Non-Prescription Health Products
- Food and Drugs Act and its regulations, including the Food and Drug Regulations and Natural Health Product Regulations
- Cannabis Act and its regulations
- Controlled Drugs and Substances Act and its regulations, including the Precursor Control Regulations and the Narcotic Control Regulations
- The United States Pharmacopeia (USP) chapter <1079> Good Storage and Distribution Practices for Drug Products for U.S. distribution



Santé Canada





Governance



Directors	Principal Occupation
Rona Ambrose ^{1 2 3} Lead Director	Deputy Chair, TD Securities
Michael Andlauer	CEO of Andlauer Healthcare Group. Founder, President and CEO of Andlauer Management Group Inc. Founder, Bulldog Capital Partners Inc.
Peter Jelley Chair	President and CEO of Bulldog Capital Partners Inc. President and CEO of Trout River Capital Ltd.
Cameron Joyce ¹	President and CEO of Accuristix from 2009 to 2015. Chair of the Board of Directors of Accuristix from 2015 to 2019.
Joseph Schlett ^{1 2 3}	Independent director with more than four decades of public accounting experience, including over 35 years with SB Partners LLP
Evelyn Sutherland 1 2* 3	CFO of Staples Canada ULC
Thomas Wellner 13*	President and CEO of Revera Inc.

¹ Independent director / ² Member of Compensation, Nominating & Governance Committee / ³ Member of the Audit Committee / * Denotes Committee Chair